NCT03554044 - T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu NegativeInvasive Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Recurrent Breast Carcinoma

Interventions

DRUG

Anastrozole

Given PO

DRUG

Exemestane

Given PO

DRUG

Fulvestrant

Given IM

DRUG

Letrozole

Given PO

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Talimogene Laherparepvec

Given IT

DRUG

Tamoxifen

Given PO

DRUG

Nab paclitaxel

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Carboplatin

Given IV

Trial Locations (1)

94143

University of California, San Francisco, San Francisco